Home Neoplasma 2023 Neoplasma Vol.70, No.1, p. 1–14, 2023

Journal info

6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal

Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.70, No.1, p. 1–14, 2023

Title: PARP in colorectal cancer: Molecular mechanisms, immunity, clinical trials, and drug combinations
Author: Fa-Hong Wu, Hang-Zhi Wei, Hong-Yang Deng, Guo-Hui Xiao, You-Cheng Zhang

Abstract: The changes in cell homeostasis in the tumor microenvironment may affect the development of colorectal cancer (CRC). Genomic instability is an important factor. Persistent genomic instability leads to epigenetic changes, and mutations are a major factor in the progression of CRC. Based on these mechanisms, it is reasonable to link poly (ADP-ribose) polymerase (PARP) with the treatment of colorectal cancer. PARP is mainly involved in DNA repair, which has an essential role in the DNA damage response and prevention of DNA damage, and maintains oxidation and superoxide redox homeostasis in the intracellular environment of the tumor. This article reviews the latest research progress on PARP and PARP inhibitors (PARPi) in CRC. It mainly includes molecular mechanisms, immunity, clinical trials, and combination strategies of CRC. The research of PARPi in CRC has broad prospects, and the combinations with other drugs are the main research direction in the future.

Keywords: PARP; colorectal cancer; DNA damage; immunity; clinical trial
Published online: 02-Sep-2022
Year: 2023, Volume: 70, Issue: 1 Page From: 1, Page To: 14

download file

© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.